IN8bio EVP gets 72,000 stock options grant

IN8bio, Inc. (INAB) reported an option grant to executive Lawrence Lamb, EVP and CSO.

Accepted by SEC EDGAR 02/06/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

IN8bio, Inc. (INAB) reported an option grant to executive Lawrence Lamb, EVP and CSO. On February 4, 2026, he received 72,000 employee stock options with a $1.96 exercise price, all held directly. Twenty-five percent vest on February 4, 2027, with the remaining options vesting in 36 equal monthly installments, contingent on his continued service.

Insider Trade Summary

Grant/Award: 72,000 shares

Grant/Award 1 txn

Insider Lamb Lawrence

Role EVP and CSO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	72,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 72,000 contracts (Direct)

Holdings Before and After: Employee Stock Option (right to buy), 0 to 72,000 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IN8bio (INAB) report for Lawrence Lamb?

IN8bio reported that EVP and CSO Lawrence Lamb received 72,000 employee stock options on February 4, 2026. These options are held directly and give him the right to buy IN8bio common stock at a fixed exercise price, subject to a multi-year vesting schedule.

What is the exercise price of Lawrence Lamb’s new IN8bio stock options?

The employee stock options granted to Lawrence Lamb have a $1.96 exercise price per share. This means he can buy IN8bio common stock at $1.96 once options vest and are exercisable, according to the vesting terms described in the Form 4 filing.

How many IN8bio stock options does Lawrence Lamb beneficially own after this grant?

After the reported transaction, Lawrence Lamb beneficially owns 72,000 employee stock options. These options are reported as directly owned and relate to IN8bio common stock, providing potential future ownership if he chooses to exercise them when vested.

What are the vesting terms for Lawrence Lamb’s IN8bio option grant?

Twenty-five percent of the 72,000 options vest on February 4, 2027. The remaining options vest in thirty-six equal monthly installments thereafter, contingent on Lamb continuing to provide service to IN8bio through each applicable vesting date.

Is Lawrence Lamb considered an officer or director in this IN8bio Form 4?

In the Form 4, Lawrence Lamb is reported as an officer of IN8bio with the title Executive Vice President and Chief Scientific Officer. He is not indicated as a director or 10% owner based on the checked relationship boxes in the filing.

Are Lawrence Lamb’s IN8bio options held directly or through another entity?

The Form 4 lists the 72,000 employee stock options as directly owned by Lawrence Lamb. There is no indication in the footnotes or ownership fields that these options are held through a trust, partnership, or other indirect ownership vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lamb Lawrence

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVE. SUITE 5330

(Street)

NEW YORK NY 10118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.96	02/04/2026		A		72,000		(1)	02/04/2036	Common Stock	72,000	$0	72,000	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attoney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.